The Endocrine Society agrees with the panel's key conclusions and believes that it is critical that the medical community determine whether testosterone treatment results in clear benefits for aging men before long-term trials are conducted. Additionally, the Society agrees that testosterone therapy should be evaluated initially as a therapeutic, not as a preventive measure for aging men. Finally, it is reasonable that clear short-term benefits of testosterone therapy be established in testosterone deficient men over the age of 65 before committing the time, energy and cost of a properly powered study of the long-term benefits and risks of testosterone therapy in this age group.
The Endocrine Society supports the IOM panel in their efforts to help the public and the medical community better understand the existing body of knowledge on testosterone therapy and develop directions for future clinical studies on testosterone therapy for older men.
The Endocrine Society supports the IOM recommendations for future clinical trials on testosterone, which include: